The characterization and development of SARS-CoV-2 monoclonal antibodies (MAbs) continue at breakneck speed. Human MAbs with potent SARS-CoV-2 neutralizing activity were described by Emanuele Andreano during the recent Global COVID Lab Meeting {1}. Another group reports here similarly potent human MAbs that protected hamsters against SARS-CoV-2 challenge.